Skip to main content
OpenTrials
Completed

NCT Number: NCT04041791

A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia

Pneumonia is one of the top causes of death in children aged below 5. More than 10% of children with severe pneumonia die. We are not sure that the currently recommended antibiotics used in children with pneumonia are the most effective. No studies have been carried out to find out whether children with pneumonia should be given intravenous (IV) fluids or nasogastric (NG) feeds.

The SEARCH trial aims to find out which antibiotics and modes of feeding are the most effective in treating children with severe pneumonia and therefore helping reduce mortality.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 month–59 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Machakos Level 5 Hospital

Machakos, Kenya

About this study

Pneumonia is one of the leading causes of death among young children with more than 10% of children aged under-five with severe pneumonia dying. The World Health Organisation (WHO) guidelines recommend the use of benzyl penicillin plus gentamicin as the standard of care of treatment for severe pneumonia. However, there have been increasing concerns about the effectiveness of the current recommendations.

Some authorities advise against the use of enteral nutrition in severely ill patients due to concerns of compromised respiratory status and risk of aspiration with nasogastric feeding. Evidence to support these concerns is lacking.

This trial aims to find out which antibiotics are the most effective in the treatment of children with severe pneumonia by comparing the current standard of care (benzyl penicillin or ampicillin plus gentamicin) to injectable ceftriaxone and injectable amoxicillin-clavulanic acid. The study will also determine whether providing feeds through a nasogastric tube is superior to intravenous fluid therapy in children with severe pneumonia.

The SEARCH trial will be a multi-site pragmatic randomised controlled trial that will assess the efficacy of both interventions in children admitted with severe pneumonia in a 3x2 factorial design. The sites will be in East Africa.

Data from the trial will be used to inform policy and contribute to guidelines and improve clinical practice in settings where the burden of pneumonia is highest.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 2 to 59 months.
  • History of cough or difficulty breathing and signs of severe pneumonia based on WHO 2013 criteria
  • Admitted to any one of the study hospitals.
  • Informed consent provided by the parents/guardian.

Exclusion criteria

  • Children presenting in cardiorespiratory arrest requiring emergency basic life support (bag-valve-mask ventilation and/or chest compressions).
  • Children for whom concurrent condition precludes the use of the first-line antibiotics for severe pneumonia such as readmission or meningitis
  • Known allergy or contraindication to penicillin, gentamicin, ceftriaxone or amoxicillin-clavulanic acid.
  • Referral from another inpatient facility following treatment with injectable antibiotics for more than 24 hours or because the first-line regimen is considered to have failed
  • Previously enrolled in the study.
  • For supportive care intervention (Intravenous fluids versus nasogastric feeds): children with absent gag reflex.
  • For supportive care intervention (Intravenous fluids versus nasogastric feeds): children unable to maintain oxygen saturations greater 90% on pulse oximetry while receiving supplemental oxygen.
  • For supportive care intervention (Intravenous fluids versus nasogastric feeds): children with severe acute malnutrition
  • For supportive care intervention (Intravenous fluids versus nasogastric feeds): shock or severe dehydration
  • For supportive care intervention (Intravenous fluids versus nasogastric feeds): Child able to feed
  • For supportive care intervention (Intravenous fluids versus nasogastric feeds): Vomiting everything

Treatment and study plan

Benzyl penicillin

Drug

Benzyl penicillin is a penicillin antibiotic.

Other names: Medipen, Cristapen

Gentamicin Sulfate

Drug

Gentamicin is an aminoglycoside antibiotic.

Other names: Gentamicin, Gentamed

Ceftriaxone

Drug

Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.

Other names: Desefin

amoxicillin clavulanate

Drug

Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.

Other names: Amoxicillin-clavulanic acid, Amoxi-clav, Amoklavin, Co-amoxiclav

Intravenous fluid

Other

Maintenance fluids administered for at least 24 hours.

Other names: Hartmann's Solution with 5% dextrose, Ringer's Lactate with 5% dextrose, Normal Saline with 5% dextrose

Nasogastric feeds

Other

Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.

Ampicillin

Drug

Ampicillin is a penicillin-type antibiotic.

Primary outcomes

  1. Mortality

    Time frame: Up to Day 5

    Mortality of participants receiving any of the injectable antibiotic treatments who die within the first five days of admission measured from source documents, medical records, verbal autopsy or death certificates.

Secondary outcomes

  1. Number of serious adverse events

    Time frame: Up to Day 30

    Serious adverse events that my be likely or definitely related to any of the interventions given to the participants. Serious adverse events include death, a life threatening event, persistent or significant disability or incapacity, hospitalisation or prolonged hospitalisation.

  2. Length of hospitalisation

    Time frame: Through duration of hospitalisation, an average of 5 days

    Total days a participant is admitted or receives inpatient care measured in days using hospital records at the start and end of each admission.

  3. Duration taken to tolerate full fluids by mouth

    Time frame: An average of 3 days

    Number of days it takes for participants to fully tolerate fluids orally.

  4. Mortality 30 days after enrollment

    Time frame: Day 30 post enrollment

    Number of participants who die within 30 days of enrollment into the study measured using source documents, medical records, verbal autopsy or death certificates.

Sponsors and collaborators

Lead sponsor

University of Oxford

Other

Collaborators

  • Department for International Development, United Kingdom
  • Kenya Ministry of Health
  • London School of Hygiene and Tropical Medicine
  • Medical Research Council
  • National Institute for Health Research, United Kingdom
  • University of Nairobi
  • Wellcome Trust

Registry information

Official study title

Supportive Care and Antibiotics for Severe Pneumonia Among Hospitalized Children (SEARCH): A Pragmatic Randomised Controlled Trial

Acronym: SEARCH

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Aug 1, 2019
Registry last updated
Jul 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.